177 related articles for article (PubMed ID: 9817627)
21. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
Zheng H; Jia F; Guo G; Quan D; Li G; Huang H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1230-1235. PubMed ID: 30643068
[TBL] [Abstract][Full Text] [Related]
22. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
[TBL] [Abstract][Full Text] [Related]
23. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
[TBL] [Abstract][Full Text] [Related]
24. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
[TBL] [Abstract][Full Text] [Related]
25. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
26. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.
Hirschmann S; Dannon PN; Iancu I; Dolberg OT; Zohar J; Grunhaus L
J Clin Psychopharmacol; 2000 Oct; 20(5):556-9. PubMed ID: 11001241
[TBL] [Abstract][Full Text] [Related]
27. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
Mundo E; Bareggi SR; Pirola R; Bellodi L; Smeraldi E
J Clin Psychopharmacol; 1997 Feb; 17(1):4-10. PubMed ID: 9004050
[TBL] [Abstract][Full Text] [Related]
28. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
Reznik I; Sirota P
J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
Goodman WK; Price LH; Rasmussen SA; Delgado PL; Heninger GR; Charney DS
Arch Gen Psychiatry; 1989 Jan; 46(1):36-44. PubMed ID: 2491940
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
Cavedini P; Erzegovesi S; Ronchi P; Bellodi L
Eur Neuropsychopharmacol; 1997 Feb; 7(1):45-9. PubMed ID: 9088884
[TBL] [Abstract][Full Text] [Related]
31. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
[TBL] [Abstract][Full Text] [Related]
32. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
[TBL] [Abstract][Full Text] [Related]
33. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
Piccinelli M; Pini S; Bellantuono C; Wilkinson G
Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
[TBL] [Abstract][Full Text] [Related]
35. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
36. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
[TBL] [Abstract][Full Text] [Related]
37. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Esalatmanesh S; Abrishami Z; Zeinoddini A; Rahiminejad F; Sadeghi M; Najarzadegan MR; Shalbafan MR; Akhondzadeh S
Psychiatry Clin Neurosci; 2016 Nov; 70(11):517-526. PubMed ID: 27488081
[TBL] [Abstract][Full Text] [Related]
38. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.
Serretti A; Zanardi R; Rossini D; Cusin C; Lilli R; Smeraldi E
Mol Psychiatry; 2001 Sep; 6(5):586-92. PubMed ID: 11526473
[TBL] [Abstract][Full Text] [Related]
39. Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study.
Zohar J; Kaplan Z; Benjamin J
J Clin Psychiatry; 1994 Mar; 55(3):86-8. PubMed ID: 8071253
[TBL] [Abstract][Full Text] [Related]
40. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial.
Rossini D; Serretti A; Franchini L; Mandelli L; Smeraldi E; De Ronchi D; Zanardi R
J Clin Psychopharmacol; 2005 Oct; 25(5):471-5. PubMed ID: 16160624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]